Inhalable Drug Market: Industry Analysis and Forecast (2021-2027) by Product, Application, and Region

Inhalable Drug Market size was valued at US$ 3.24 Bn. in 2020 and the total revenue is expected to grow at 4.3% through 2021 to 2027, reaching nearly US$ 4.35 Bn.

Inhalable Drug Market Overview:

Inhaled drugs, commonly referred to as "inhalants," are a class of chemicals that people inhale into their lungs to get high. This is frequently done by young individuals or those who lack the financial means to acquire more expensive alcoholic beverages. The growing prevalence of pulmonary disorders has provided enormous prospects in the global market for inhalable medications. The usage of inhalation devices by individuals with breathing problems is not a new occurrence. As a result, the market for inhalable medications has been steadily growing. Inhalable Drug Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2027. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done good in lockdown also and specific strategic analysis of those companies is done in the report

Inhalable Drug Market Dynamics:

The rising prevalence of respiratory illnesses such as COPD, asthma, and cystic fibrosis is expected to drive market expansion. According to the Centers for Disease Control and Prevention (CDC), asthma affected more than 25 million individuals in the US. in 2017, accounting for 7.7% of the adult population and 8.4% of children. The rising frequency of non-respiratory disorders including diabetes and Parkinson's disease is predicted to drive demand for inhalable medications. Parkinson's disease is commonly diagnosed in persons over the age of 60. With age, the prevalence of this condition rises. According to the World Health Organization, the percentage of people aged 60 and over is expected to double from 12% in 2015 to 22% by 2050. As a result, producers are working on inhalable medications that will be easier to administer to the elderly. For example, the USFDA authorized INBRIJA, a prescription drug containing levodopa, for adults in December 2019. Market growth is likely to be fueled by advancements in inhalable pharmaceuticals. Surfactant carriers, nanocrystals, and micro and nanoparticles are all used in advanced inhalation therapy. As a result, small-molecule research is being done to produce new inhalable medications. Inhalation therapy has better drug systemic availability, convenience over invasive techniques, improved drug interactions, and less toxicity. Market participants are seeing new growth potential when existing non-inhaled compounds are reformulated into inhaled molecules for improved drug delivery. Strategic Mergers and acquisitions, product launches, are projected to lift the growth of the market in the forecast period. such as Glenmark Pharmaceuticals, for example, signed a license agreement in August 2018 to market Tiotropium Bromide dry powder inhaler to treat COPD in Europe.

Inhalable Drug Market Segment Analysis:

The Dry Powder Formulations segment is dominating the Product segment of the Inhalable Drug Market:

In 2019, the inhalable medicine market was led by dry powder formulations, which had higher efficacy and better results than other forms. Furthermore, the formulation's leading market share is due to the presence of a diverse product portfolio and a solid pipeline. Manufacturers' focus on producing small-sized particle products has shifted, which is expected to fuel market expansion over the forecast period. Cipla, for example, unveiled Niveoli in April 2019, the first extra-fine particle inhaler created in India. In asthma and Chronic obstructive pulmonary patients, the inhaler contains beclomethasone-formoterol and hydrofluoroalkane (HFA), which ensures targeted delivery to tiny airways. The Respiratory Diseases segment is considered to supplement the growth of the Inhalable Drug Market. The respiratory diseases segment dominated the growth of the market with a market share of 41.6% in 2019. Chronic respiratory diseases like asthma, COPD, and bronchospasm, as well as non-respiratory diseases like diabetes and Parkinson's disease, are commonly treated with inhalable medications. Owing to its effectiveness, ability to reduce pulmonary inflammation, and reduced need for hospitalization, combination therapy of Inhaled Corticosteroid (ICS), Long-Acting Muscarinic Antagonist (LAMA), and Long-Acting 2 Adrenoceptor Agonist (LABA) is widely used for the treatment of COPD and asthma. As a result, many pharmaceutical companies have developed combination medicines. For example, in September 2017, the US Food and Drug Administration authorized Trelegy Ellipta, a combination medication for Chronic Obstructive Pulmonary Diseases (COPD), chronic bronchitis, and emphysema. Fluticasone furoate (ICS), umeclidinium (LAMA), and vilanterol are the active compounds in this drug (LABA). Hence, new product launches by the market players is likely to lift the growth of the market in the forecast period. Inhalable Drug Market by Application

Inhalable Drug Market Regional Insights:

North America is estimated to dominate the growth of the Inhalable Drug Market. In terms of revenue, North America led the market in 2019, followed by Europe. Both markets for inhalable medications are fueled by numerous governments, organizations, and company-led awareness campaigns aimed at improving COPD treatment alternatives. For example, in November 2016, Mylan held a COPD Awareness Month to raise awareness about different therapies (inhaled and other bronchodilators) and dosage types. Further, increase in research and development by contract manufactures and government organizations, technological advancement is likely to fuel the growth of the market in the forecast period. Over the projected period, the Asia Pacific market for inhalable pharmaceuticals is expected to develop at the quickest rate. This is due to a variety of factors, including improved healthcare infrastructure, increased patient knowledge, and increased disposable income of individuals. Furthermore, new market entries result in fierce rivalry, which is predicted to play a key part in creating a growth platform for this regional market in the coming years. Growing medical tourism in several Asian nations is catching the interest of major global players, who are looking to establish operations in several rising economies with strong growth potential. Inhalable Drug Market by Regional The objective of the report is to present a comprehensive analysis of the Inhalable Drug Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Inhalable Drug Market dynamics, structure by analyzing the market segments and project the Inhalable Drug Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Inhalable Drug Market make the report investor’s guide.

Inhalable Drug Market Scope: Inquire before buying

Inhalable Drug Market by Scope

Inhalable Drug Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Inhalable Drug Market Key Player

Teva Pharmaceutical Industries LtdCipla Inc • Amneal Pharmaceuticals Inc • Glenmark Pharmaceuticals Inc • AstraZeneca • Vectura • Sanofi • Mylan • Mundipharma • GlaxoSmithKline • Boehringer Ingelheim International GmbH • Sunovion Pharmaceuticals, Inc. • Philips Healthcare • CareFusion Corporation • Roche Diagnostics • Regeneron • Genentech, Inc. • Sumitomo Dainippon

FAQs:

1. What is the Inhalable Drug market value in 2020? Ans: Inhalable Drug market value in 2020 was estimated as 3.24 Billion USD. 2. What is the Inhalable Drug market growth? Ans: The Inhalable Drug market is anticipated to grow with a CAGR of 4.3% in the forecast period and is likely to reach USD 4.35 Billion by the end of 2027. 3. Which product segment is expected to dominate the Inhalable Drug market during the forecast period? Ans: Dry powder formulation dominated the inhalable drugs market in 2019 owing to higher efficacy and better results in comparison with other forms. 4. Who are the key players in the Inhalable Drug market? Ans: Some key players operating in the Inhalable Drug market include AstraZeneca; Sanofi; Vectura; Mylan; GlaxoSmithKline; Mundipharma; Boehringer Ingelheim International GmbH; and Cipla Inc. among others. 5. What is the key driving factor for the growth of the Inhalable Drug market? Ans: Increasing prevalence of respiratory diseases such as Chronic Obstructive Pulmonary Diseases (COPD), asthma, and cystic fibrosis is anticipated to boost the market growth.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Inhalable Drug Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2020 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Inhalable Drug Market 3.4. Geographical Snapshot of the Inhalable Drug Market, By Manufacturer share 4. Inhalable Drug Market Overview, 2020-2027 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porter Five Forces Analysis 4.1.6.1. The threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. The threat of Substitute Grades 4.1.6.5. The intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Inhalable Drug Market 5. Supply Side and Demand Side Indicators 6. Inhalable Drug Market Analysis and Forecast, 2020-2027 6.1. Inhalable Drug Market Size & Y-o-Y Growth Analysis. 7. Inhalable Drug Market Analysis and Forecasts, 2020-2027 7.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 7.1.1. Aerosol 7.1.2. Dry Powder Formulation 7.1.3. Spray 7.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 7.2.1. Respiratory Diseases 7.2.2. Non-Respiratory Disease 8. Inhalable Drug Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2020-2027 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Inhalable Drug Market Analysis and Forecasts, 2020-2027 9.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 9.1.1. Aerosol 9.1.2. Dry Powder Formulation 9.1.3. Spray 9.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 9.2.1. Respiratory Diseases 9.2.2. Non-Respiratory Disease 10. North America Inhalable Drug Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Inhalable Drug Market Analysis and Forecasts, 2020-2027 11.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 11.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 12. Canada Inhalable Drug Market Analysis and Forecasts, 2020-2027 12.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 12.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 13. Mexico Inhalable Drug Market Analysis and Forecasts, 2020-2027 13.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 13.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 14. Europe Inhalable Drug Market Analysis and Forecasts, 2020-2027 14.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 14.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 15. Europe Inhalable Drug Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Inhalable Drug Market Analysis and Forecasts, 2020-2027 16.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 16.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 17. France Inhalable Drug Market Analysis and Forecasts, 2020-2027 17.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 17.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 18. Germany Inhalable Drug Market Analysis and Forecasts, 2020-2027 18.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 18.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 19. Italy Inhalable Drug Market Analysis and Forecasts, 2020-2027 19.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 19.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 20. Spain Inhalable Drug Market Analysis and Forecasts, 2020-2027 20.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 20.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 21. Sweden Inhalable Drug Market Analysis and Forecasts, 2020-2027 21.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 21.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 22. CIS Countries Inhalable Drug Market Analysis and Forecasts, 2020-2027 22.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 22.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 23. Rest of Europe Inhalable Drug Market Analysis and Forecasts, 2020-2027 23.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 23.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 24. Asia Pacific Inhalable Drug Market Analysis and Forecasts, 2020-2027 24.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 24.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 25. Asia Pacific Inhalable Drug Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2020-2027 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Inhalable Drug Market Analysis and Forecasts, 2020-2027 26.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 26.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 27. India Inhalable Drug Market Analysis and Forecasts, 2020-2027 27.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 27.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 28. Japan Inhalable Drug Market Analysis and Forecasts, 2020-2027 28.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 28.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 29. South Korea Inhalable Drug Market Analysis and Forecasts, 2020-2027 29.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 29.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 30. Australia Inhalable Drug Market Analysis and Forecasts, 2020-2027 30.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 30.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 31. ASEAN Inhalable Drug Market Analysis and Forecasts, 2020-2027 31.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 31.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 32. Rest of Asia Pacific Inhalable Drug Market Analysis and Forecasts, 2020-2027 32.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 32.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 33. Middle East Africa Inhalable Drug Market Analysis and Forecasts, 2020-2027 33.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 33.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 34. Middle East Africa Inhalable Drug Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Inhalable Drug Market Analysis and Forecasts, 2020-2027 35.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 35.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 36. GCC Countries Inhalable Drug Market Analysis and Forecasts, 2020-2027 36.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 36.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2020-2027 37.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 37.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 38. Nigeria Inhalable Drug Market Analysis and Forecasts, 2020-2027 38.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 38.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 39. Rest of ME&A Inhalable Drug Market Analysis and Forecasts, 2020-2027 39.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 39.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 40. South America Inhalable Drug Market Analysis and Forecasts, 2020-2027 40.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 40.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 41. South America Inhalable Drug Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2020-2027 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Inhalable Drug Market Analysis and Forecasts, 2020-2027 42.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 42.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 43. Argentina Inhalable Drug Market Analysis and Forecasts, 2020-2027 43.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 43.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 44. Rest of South America Inhalable Drug Market Analysis and Forecasts, 2020-2027 44.1. Market Size (Value) Estimates & Forecast By Product, 2020-2027 44.2. Market Size (Value) Estimates & Forecast By Application, 2020-2027 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Inhalable Drug Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile: Key Players 45.3.1. Novartis AG 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Development 45.3.2. AstraZeneca 45.3.3. Vectura 45.3.4. Sanofi 45.3.5. Mylan 45.3.6. Mundipharma 45.3.7. GlaxoSmithKline 45.3.8. Boehringer Ingelheim International GmbH 45.3.9. Cipla Inc. 45.3.10. Sunovion Pharmaceuticals, Inc. 45.3.11. Teva Pharmaceutical Industries 45.3.12. Philips Healthcare 45.3.13. CareFusion Corporation 45.3.14. Roche Diagnostics 45.3.15. Regeneron 45.3.16. Genentech, Inc. 45.3.17. Sumitomo Dainippon 46. Primary Key Insights

About This Report

Report ID123389
Category Healthcare
Published DateOct 2021
Updated Date
Contact Us